PAR 2.04% 24.0¢ paradigm biopharmaceuticals limited..

research reports and media, page-2410

  1. 838 Posts.
    lightbulb Created with Sketch. 339
    TanamiRod, FarmerBob has shared the Research note by Cap 51. Re Lockup etc there is no longer a lockup, the fund can offload anytime. However, I know first hand they are holding for the LONG Term (post registration) with a view to a bigger pay day. Unlike all the other funds, Cap 51 have actually hived our PAR Holdings out of the main fund (rather than having to off load them (due to risk mitigation) when they were around $4.00. Usually a fund will de-risk by selling as the price increases so it does not become to big a portion of the fund hence impacting comparitive returns (negitively and positivly).

    RE the Take over TanamiRod.. Yep Im well aware of the process and the following will potentially be miscontrued to a takeover is happening (which we dont actually know) but...
    Say Im a big pharma thats missed out getting a previous OA drug up, they know the market, they approach PAR to get access to the TOP secret data room in the guise of a partnership, they can see that this is a "BlockBuster" and they understand the dynamics and size of the market... they asses the company structure, go to 4.9%, quiet chat with the chairman, lob a too good to be true Bid ($20 would seem like alot based on the current price) board recommends... Game over... Now if they were really smart they would wait till we anounce DMOD from 008, which should drive this thing close to $0.00 (even with $40m) in the bank and sending poor old Beaza79 into apoplexy.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
24.0¢
Change
-0.005(2.04%)
Mkt cap ! $83.98M
Open High Low Value Volume
25.0¢ 25.5¢ 24.0¢ $202.2K 814.1K

Buyers (Bids)

No. Vol. Price($)
5 181098 24.0¢
 

Sellers (Offers)

Price($) Vol. No.
25.0¢ 118621 5
View Market Depth
Last trade - 16.10pm 15/11/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.